Active, not recruitingPhase 2NCT04458610

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Jan A Burger, M.D
M.D. Anderson Cancer Center
Intervention
Rituximab(biological)
Enrollment
60 target
Eligibility
18 years · All sexes
Timeline
2020 – 2026

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04458610 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials